195 related articles for article (PubMed ID: 11498220)
1. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
2. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
3. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
4. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
5. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
6. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
7. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
8. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
9. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
Riemenschneider MJ; Koy TH; Reifenberger G
Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
11. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
12. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
13. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
14. Overview and recent advances in neuropathology. Part 1: Central nervous system tumours.
Robertson T; Koszyca B; Gonzales M
Pathology; 2011 Feb; 43(2):88-92. PubMed ID: 21233669
[TBL] [Abstract][Full Text] [Related]
15. OLIG-1 and 2 gene expression and oligodendroglial tumours.
Hoang-Xuan K; Aguirre-Cruz L; Mokhtari K; Marie Y; Sanson M
Neuropathol Appl Neurobiol; 2002 Apr; 28(2):89-94. PubMed ID: 11972795
[TBL] [Abstract][Full Text] [Related]
16. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
17. Can oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms?
Kurdi M; Alkhatabi H; Butt N; Albayjani H; Aljhdali H; Mohamed F; Alsinani T; Baeesa S; Almuhaini E; Al-Ghafari A; Hakamy S; Faizo E; Bahakeem B
Folia Neuropathol; 2021; 59(4):350-358. PubMed ID: 35114775
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors.
Aguirre-Cruz L; Mokhtari K; Hoang-Xuan K; Marie Y; Criniere E; Taillibert S; Lopes M; Delattre JY; Sanson M
J Neurooncol; 2004 May; 67(3):265-71. PubMed ID: 15164981
[TBL] [Abstract][Full Text] [Related]
19. Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas.
Okada M; Yano H; Hirose Y; Nakayama N; Ohe N; Shinoda J; Iwama T
Brain Tumor Pathol; 2011 Apr; 28(2):157-61. PubMed ID: 21312066
[TBL] [Abstract][Full Text] [Related]
20. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
